Search PubMed⌕ Search

Biomedical subjects

Dawn A Marcus

Publications and source records attributed to Dawn A Marcus.

27 records · Page 2Linked to original sources

Gender differences in chronic pain in a treatment-seeking population.

OBJECTIVE: To compare pain characteristics, disability, and comorbid psychological distress between genders in a treatment-seeking sample of patients with chronic pain. METHODS: Consecutive patients with chronic pain were evaluated and assigned a pain diagnosis. Gender differences were compared on responses to questions about pain symptoms, associated disability, and psychological distress. RESULTS: The pain sample (N = 716) was predominately female (63%). Pain locations, diagnoses, and trigger factors were similar in male and female patients. Male patients reported a greater mean pain severity (7.16 males vs 6.82 females; P = 0.05), greater pain constancy (41.2% vs 26.7%; P < 0.001), and more days per week with pain (6.37 vs 5.87; P < 0.001). In addition, males reported higher levels of disability, with reduced activity more than 3 days per week in 70.2% of males and 56.0% of females, and complete disability more than 3 days per week in 55.9% of males and 37.3% of females (P < 0.001). Quality of life measures were additionally reduced for both physical and psychological categories in men versus women (P = 0.05 to < 0.01). CONCLUSIONS: There are important gender differences in treatment-seeking patients with chronic pain. Males report higher levels of pain and disability, with reduced physical and psychological quality of life, as compared to females. These differences in treatment-seeking patients may reflect gender differences in treatment-seeking behavior.

Adult↗

A controlled study of minimal-contact thermal biofeedback treatment in children with migraine.

OBJECTIVE: To evaluate the effectiveness of handwarming biofeedback (HWB) and stress management training in comparison to attention (handcooling, HCB) and wait-list control groups. Thermal biofeedback has been used in many pediatric migraine treatment studies and has demonstrated a consistent therapeutic effect. No published studies to date have compared this treatment modality with credible attention control using biofeedback technology. METHODS: Thirty-six children and adolescents (mean age: 12.8 years), as well as the mothers and fathers of these children enrolled in the study, were randomly assigned to the three groups. Thirty-four children completed treatment. Both treatment groups received four sessions of biofeedback training and a portable biofeedback device for home practice. Ratings of treatment credibility showed that the children rated the two treatments as equally credible. Assessment included anxiety and depression questionnaires for the children and both of their parents. RESULTS: Children who had been assigned to the HWB group were more likely to achieve clinical improvement in migraine after treatment than the children in the HCB group. Treatment gains were maintained up to 6 months after treatment. Home practice data reflected a general increase in temperature in the HWB group and a decrease in temperature for the HCB group. CONCLUSIONS: The results of this study confirm the findings of earlier pediatric migraine biofeedback treatment studies and also provide support for the specific effect of treatments including stress management and HWB. Future studies with larger sample sizes will aid in delineating the appropriateness of HCB as a control treatment.

Adolescent↗

Pharmacoeconomics of opioid therapy for chronic non-malignant pain.

Chronic non-malignant pain (CNMP) is widely prevalent and associated with significant costs. Costs related to chronic pain include medical services and medications, treatment of medication-related toxicity and work absenteeism. The use of non-narcotic analgesics is associated with inadequate pain-relief for many patients, as well as significant and costly organ toxicity. When used appropriately and judiciously, opioid medications can be a useful addition to the treatment plan for patients with CNMP. Opioids can provide long-term, safe and cost-effective pain relief.

Analgesics, Opioid↗

Pregnancy and chronic headache.

Headache patterns in women change in relation to fluctuations in oestrogen levels. Increasing oestrogen levels in early pregnancy offer a protective effect against headache, particularly for women with migraine. However, some women continue to experience troublesome headache throughout pregnancy. Headache persisting at the end of the first trimester will usually continue without improvement for the remainder of pregnancy and should be treated. Safe and effective acute care treatment options include paracetamol, opioids and anti-emetics. The use of triptans during pregnancy is controversial and not broadly recommended. Safe and effective preventive treatments include relaxation, biofeedback, beta-blockers, some antidepressants and gabapentin in early pregnancy.

Animals↗

Interrelationships of neurochemicals, estrogen, and recurring headache.

Recurring headache syndromes, such as migraine, are common problems for women throughout their adult lives. Headache symptoms often fluctuate over the years that they are present and, for most headache sufferers, these changes seem to occur randomly. For many women, however, chronic headache changes in predictable patterns in relation to alterations in hormonal states. Clinically, headache is often modified during menses, pregnancy, and menopause. Although sex hormones are changing with these clinical events, this paper will present the more important link between altered sex hormones and changes in neurochemicals believed to be responsible for recurring headache syndromes according to the neurobiological theory of migraine.

Adult↗

Obesity and the impact of chronic pain.

OBJECTIVE: To evaluate obesity as a marker for increased pain severity, disability, and psychologic distress in treatment-seeking, mixed chronic pain patients. METHODS: Three hundred seventy-two consecutive chronic pain patients seeking evaluation at a university pain clinic were divided into 3 weight categories, based on body mass index (BMI): normal (BMI < 25 kg/m2), overweight (BMI between 25 kg/m and 30 kg/m2), and obese (BMI > or = 30 kg/m2). Patients completed questionnaires to identify pain severity, disability, depression, anxiety, and quality of life. RESULTS: Pain severity and days per week with pain were similar among the weight groups. Disability was related to increasing weight status, with increased BMI associated with more days per week with both reduced activity and complete disability. Depressive symptoms were also related to weight category, with an average Beck Depression Inventory score of 11.81 +/- 7.55 in normal, 12.88 +/- 11.64 in overweight, and 15.78 +/- 9.88 in obese patients. Anxiety scores were similar among the weight categories. Physical function domain of quality of life was also reduced in relation to weight. CONCLUSIONS: Weight is associated with co-morbid disability, depression, and reduced quality of life for physical function in chronic pain patients. Calculation of the BMI should become a routine part of the screening evaluation for chronic pain patients, with additional screening for disability and psychologic distress in patients with elevated BMIs.

Activities of Daily Living↗

Sustained-release oxycodone dosing survey of chronic pain patients.

OBJECTIVE: To determine the dosing of sustained-release oxycodone that is typically prescribed to achieve pain relief in a mixed group of chronic pain patients. METHODS: One hundred twenty-eight chronic pain patients prescribed stable doses of sustained-release oxycodone for at least 6 months were identified through chart review. Total daily dosing for both long- and short-acting opioids were recorded for each patient. RESULTS: The prescribed frequency of dosing sustained-release oxycodone determined through clinical practice was twice daily for 33% of patients, with 67% requiring greater than twice daily dosing. Ninety-three percent of those using greater than twice daily dosing were prescribed sustained-release oxycodone 3 times daily. The median dose of sustained-release oxycodone was 80 mg for patients prescribed twice daily dosing, 60 mg when prescribed 3 times daily, and 120 mg when 4 times daily. Regularly scheduled, daily supplemental short-acting opioids were used by 47% of patients prescribed twice daily sustained-release oxycodone and 21% prescribed greater than twice daily dosing. The median total oxycodone-equivalent daily dosage (short- + long-acting opioids) was 80 mg for patients treated with either twice daily or greater than twice daily dosing. CONCLUSION: In a mixed group of chronic pain patients referred to a university pain management clinic, sustained-release oxycodone was prescribed more often than twice daily (usually every 8 hours) in 67% of patients. Patients maintained on every-12-hour dosing were twice as likely to use regularly scheduled, daily, short-acting opioids to achieve pain relief.

Adult↗